Second primary malignancies in thyroid cancer patients.

Area of Science:

• Oncology
• Nuclear Medicine
• Epidemiology

Background:

• Assessing late health effects of radioiodine ((131)I) therapy for thyroid cancer is challenging due to limited patient numbers per center.
• Second primary malignancies (SPMs) are a potential long-term concern for thyroid cancer survivors.

Purpose of the Study:

• To evaluate the risk of SPMs in a European cohort of thyroid cancer patients treated with radioiodine ((131)I).
• To investigate the relationship between cumulative (131)I activity and the incidence of SPMs.

Main Methods:

• Pooling data from Swedish, Italian, and French cohorts of papillary and follicular thyroid cancer patients (6841 patients, diagnosed 1934-1995).
• Time-dependent analysis using external comparison with general population rates.
• Analysis of SPM risk based on cumulative (131)I activity and specific cancer types.

Main Results:

• An overall 27% significantly increased risk of SPM was observed in the European cohort compared to the general population.
• Increased risk of both solid tumors and leukemias correlated with higher cumulative (131)I activity.
• Specific associations found between (131)I administration and bone/soft tissue, colorectal, and salivary gland cancers.

Conclusions:

• Radioiodine ((131)I) treatment for thyroid cancer is associated with a significant increased risk of second primary malignancies.
• The risk of SPMs, including solid tumors and leukemias, increases with cumulative (131)I dosage.
• Clinical guidelines should emphasize careful patient selection for (131)I therapy to maximize benefits and minimize risks.